(Q44440459)

3 December 2017

Use of isoniazid for latent tuberculosis infection in a public health clinic (English)

1 reference

3 December 2017

Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic (English)

1 reference

https://api.crossref.org/works/10.1164/RCCM.200303-390OC

2 January 2024

0 references

1 reference

1 reference

0 references

Philip A. LoBue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12746255

2 January 2024

Kathleen S. Moser

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12746255

2 January 2024

language of work or name

English

0 references

publication date

13 May 2003

1 reference

full work available at URL

3 December 2017

https://www.atsjournals.org/doi/pdf/10.1164/rccm.200303-390OC

1 reference

https://api.crossref.org/works/10.1164/RCCM.200303-390OC

American Journal of Respiratory and Critical Care Medicine

2 January 2024

published in

1 reference

3 December 2017

168

1 reference

3 December 2017

443-447

1 reference

3 December 2017

4

1 reference

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

3 December 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200303-390OC

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200303-390OC

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200303-390OC

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200303-390OC

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200303-390OC

Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200303-390OC

Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200303-390OC

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200303-390OC

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200303-390OC

Isoniazid-associated hepatitis. Report of an outbreak

21 January 2018

series ordinal

5

1 reference

https://api.crossref.org/works/10.1164/RCCM.200303-390OC

Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic

2 January 2024

series ordinal

8

1 reference

https://api.crossref.org/works/10.1164/RCCM.200303-390OC

2 January 2024

Identifiers

1 reference

3 December 2017

1 reference